IMMUNIZATIONS – Adds to existing law to establish provisions regarding limitation of distribution and waiver of immunity for certain human gene therapy products.

This Idaho bill (S 1189) requires manufacturers of human gene therapy products for infectious diseases to waive legal immunity from lawsuits related to design defects before distributing, selling, or administering these products in Idaho. It directly affects pharmaceutical companies producing gene therapies for conditions like viral infections. The key provision mandates that manufacturers explicitly give up immunity (including protections under federal vaccine injury law) for injuries caused by design flaws in these therapies. The law takes effect July 1, 2025, and defines "human gene therapy products" to include genetically modified cells, viral vectors, and other genetic treatments.